Q1 EPS Estimates for Mersana Therapeutics Cut by Wedbush

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – Research analysts at Wedbush reduced their Q1 2025 EPS estimates for shares of Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.25) per share for the quarter, down from their previous estimate of ($0.24). Wedbush has a “Outperform” rating and a $4.00 price target on the stock. The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. Wedbush also issued estimates for Mersana Therapeutics’ Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.94) EPS, FY2026 earnings at ($0.75) EPS and FY2027 earnings at ($0.70) EPS.

Several other analysts have also issued reports on MRSN. William Blair initiated coverage on shares of Mersana Therapeutics in a report on Thursday, February 6th. They issued an “outperform” rating on the stock. Citigroup assumed coverage on shares of Mersana Therapeutics in a research note on Friday, November 15th. They set a “buy” rating and a $5.00 target price on the stock. Two analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $4.25.

Mersana Therapeutics Trading Up 0.8 %

Shares of MRSN stock opened at $0.51 on Thursday. The company’s 50-day moving average price is $0.79 and its 200-day moving average price is $1.56. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 13.35. The stock has a market cap of $63.30 million, a price-to-earnings ratio of -0.84 and a beta of 1.39. Mersana Therapeutics has a twelve month low of $0.46 and a twelve month high of $6.28.

Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.05. The firm had revenue of $16.36 million for the quarter, compared to analysts’ expectations of $7.71 million. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%.

Hedge Funds Weigh In On Mersana Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. US Bancorp DE acquired a new stake in shares of Mersana Therapeutics in the third quarter valued at approximately $31,000. Los Angeles Capital Management LLC boosted its holdings in shares of Mersana Therapeutics by 8.1% in the third quarter. Los Angeles Capital Management LLC now owns 189,660 shares of the company’s stock valued at $358,000 after acquiring an additional 14,240 shares during the period. GSA Capital Partners LLP lifted its holdings in shares of Mersana Therapeutics by 368.9% during the third quarter. GSA Capital Partners LLP now owns 271,774 shares of the company’s stock worth $514,000 after purchasing an additional 213,814 shares during the period. Intech Investment Management LLC acquired a new stake in shares of Mersana Therapeutics during the third quarter worth $52,000. Finally, HealthInvest Partners AB lifted its holdings in shares of Mersana Therapeutics by 191.3% during the third quarter. HealthInvest Partners AB now owns 538,621 shares of the company’s stock worth $1,018,000 after purchasing an additional 353,721 shares during the period. 93.92% of the stock is owned by institutional investors and hedge funds.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.